Esperion Therapeutics | ESPR - Equity Capital And Reserves


Esperion Therapeutics reported $-451.36M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Alterity Therapeutics Limited AUD 22.81M 5.29M Jun/2023
Amarin USD 458.89M 6.03M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Cipla INR 329.19B 16.3B Sep/2025
CSL USD 21.41B 861M Jun/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Geron USD 248.71M 10.82M Sep/2025
Grifols EUR 6.08B 34.72M Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Moderna USD 9.33B 69M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
United Therapeutics USD 6.59B 583.4M Sep/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025